# A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Source: https://onco.cc/trials/nct06246110/  
OnCo record `nct06246110` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of EIK1001, Pembrolizumab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Eikon Therapeutics, active and no longer recruiting.

## Summary

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC is a phase 2 interventional study registered as NCT06246110 by Eikon Therapeutics, with 70 participants enrolled, started 2024-02-06 and due to reach its primary completion in 2026-12. Interventions recorded: EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed and Carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06246110
- Phase: 2
- Setting: A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
- Sponsor: Eikon Therapeutics
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06246110: https://clinicaltrials.gov/study/NCT06246110

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [EIK1001](https://onco.cc/drugs/eik1001/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06246110.json